AgingResearch.NewsJoin free
Acta Neurologica Belgica

Diabetes drugs linked to lower death risk in vascular dementia

One-year mortality was 8.7% among people taking the drugs, compared with 15.9% among matched non-users.

Paper by Daniel Mandel, Pranjal Rai, Huanwen Chen, +15 more authorsDhairya A. Lakhani
Figure 1 from Acta Neurologica Belgica
Open the figure at full size
Figure 1. Mandel et al.

Our read

Populations
Studied:
Cohort study of patients with vascular dementia, 5 years, against matched GLP-1RA non-users
What changed:
Death at one year was lower among drug users: 8.7% versus 15.9% among non-users
The catch:
Differences in health or care between users and non-users could explain the mortality gap
In the record:
The 1,429th paper on GLP-1 receptor agonists with results in people; 4,847 on record in all. Its result on mortality agrees with 198 of 219 other findings on record; 2 point the other way and 19 found no change.

Editor of record: Boris Djordjevic · AgingResearch.News

Paper
Follow @agingbrief

Patients with vascular dementia were identified in a national database from 2016 to 2025 for a retrospective cohort study. The researchers matched 613 people receiving glucagon-like peptide-1 receptor agonists, a class of diabetes drugs, within one month of diagnosis with 613 non-users with similar measured characteristics.

Drug use was associated with lower mortality at all three follow-up points. Mortality among users versus non-users was 8.7% versus 15.9% at one year, 23.3% versus 33.8% at three years, and 34.4% versus 54.3% at five years. Drug use was also associated with lower risks of hospital admission and emergency visits.

Why it matters

Vascular dementia has no treatment shown to improve survival or reduce acute care use. The findings support prospective randomized trials to test whether these drugs could help.

Caveats

Matching could not rule out differences in health or care between drug users and non-users that might account for their different outcomes. The findings concern people with established vascular dementia, not dementia prevention.

Where the evidence stands

GLP-1 receptor agonists

Cells, worms or flies, mice and humans: replicated by independent labs.

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

No results posted: trials that ended over a year ago with no results on ClinicalTrials.gov and no paper reporting them.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 986 independent labs in 86 countries
  • 729 findings against
  • 1,257 trials, 313 with no results posted
  • Funders: Eli Lilly and Company and others
  • 1,721 of 7,033 findings with company ties
  • 757 of 1,257 trials sponsored by its developers

Comments

Be the first to comment.

More peptides

More on GLP-1 receptor agonists